Harnessing viral specific immunity for fighting cancer
Trojan Bio is developing a novel class of therapeutic antibodies for the treatment of solid tumors. The company's Trojan antibody platform integrates viral peptides into antibody structures, enabling them to penetrate tumor microenvironments and activate the immune system from within—harnessing antiviral immunity to fight cancer. Trojan Bio won the Biomed Israel 2025 Startup Competition and is backed by Peregrine Ventures.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNo funding data available yet.
Know something? Help us improve our data.
Create a free account to see which investors have funded this company.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
